Jinyuan EP (000546) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
10 Feb, 2026Executive summary
Revenue surged 136.79% year-over-year to ¥6.73 billion, driven by strong growth in resource utilization business.
Net profit attributable to shareholders was ¥39.71 million, reversing a loss of ¥678.33 million last year.
Cash flow from operations turned negative at -¥517.18 million, mainly due to increased inventory and reduced customer prepayments.
The company focused on environmental protection and new energy materials, with significant progress in lithium projects.
Financial highlights
Operating income: ¥6.73 billion, up 136.79% year-over-year.
Net profit attributable to shareholders: ¥39.71 million, up 105.85% year-over-year.
Gross margin for resource utilization business remained stable; non-recurring gains boosted net profit.
Basic and diluted EPS: ¥0.05, compared to -¥0.87 last year.
Total assets at year-end: ¥5.63 billion, down 25.78% from prior year.
Outlook and guidance
Plans to accelerate development of the Tibet Bachen Co Salt Lake lithium project and optimize production efficiency.
Will continue to expand overseas lithium resources, especially in Argentina and Africa.
Focus on cost reduction and efficiency improvement in environmental business, with potential divestment of underperforming subsidiaries.
No cash dividend, bonus share, or capital reserve transfer planned for the year.
Latest events from Jinyuan EP
- Revenue up 187% and net profit returns positive, driven by resource utilization growth.000546
Q2 202410 Feb 2026 - Revenue and net profit soared year-over-year, led by waste resource utilization growth.000546
Q3 202410 Feb 2026 - Revenue soared but net profit and cash flow declined amid margin pressure and ownership change.000546
Q1 202510 Feb 2026 - Revenue up 59.05% YoY, but net loss and margin pressure amid sector overcapacity and cost rises.000546
Q2 202510 Feb 2026 - Revenue up 50% year-over-year, but net loss deepened due to higher costs and impairments.000546
Q3 202510 Feb 2026